Cartesian Therapeutics, Inc. beat EPS estimates 0% of the time across 2 reported quarters (0 beats, 2 misses), averaging -71.0% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | not reported | $0.46 | not reported | not reported | |
| Q1 FY26 | $-0.84 | $-1.46 | -73.8% | Miss | |
| Q4 FY25 | $-0.82 | $-1.38 | -68.3% | Miss |
Back to RNAC overview · RNAC holders · RNAC KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.